Zinger Key Points
- Hims & Hers shares rise 5.12% following the appointment of Kåre Schultz to its Board of Directors.
- Schultz’s extensive pharmaceutical experience is expected to enhance Hims & Hers' mission to improve access to health and wellness solutions
- Get real-time earnings alerts before the market moves and access expert analysis that uncovers hidden opportunities in the post-earnings chaos.
Hims & Hers Health Inc. HIMS shares are moving higher on Monday after the company appointed former Novo Nordisk COO and President Kåre Schultz‘s to its Board of Directors.
Schultz brings extensive experience from his leadership roles at Novo Nordisk Inc. NVO, Teva Pharmaceutical Industries LTD TEVA and Lundbeck.
At Novo Nordisk, Schultz was instrumental in establishing the company as a leader in diabetes care.
“Kåre’s experience gives us an incredible wealth of expertise as we bring together the most valuable elements of clinical excellence, healthcare and technology to redefine health and wellness for our customers.” said CEO Andrew Dudum.
Price Action: Hims & Hers shares were up by 5.12% at $20.50 at the time of writing, according to Benzinga Pro.
See Also:
Image: Courtesy of Hims & Hers Health, Inc.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
